EQUILLIUM, INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3
EQUILLIUM, INC. (EQ) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3 of $0 for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-26.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation › Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3 · last filed 2020-03-26
- EQUILLIUM, INC. fair value, measurement with unobservable inputs reconciliation, liability, transfers into level 3 for the quarter ending 2018-12-31 was $0.00.
- EQUILLIUM, INC. fair value, measurement with unobservable inputs reconciliation, liability, transfers into level 3 for fiscal 2019 was $0.00.
- EQUILLIUM, INC. fair value, measurement with unobservable inputs reconciliation, liability, transfers into level 3 for fiscal 2018 was $0.00.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3 12 month |
|---|---|---|---|
| 2019-12-31 | $0.00 10-K · filed 2020-03-26 | ||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-27 | $0.00 10-K · filed 2019-03-27 | |
| 2018-09-30 | $0.00 10-Q · filed 2018-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |